BioAtla Q1 net loss $27.5M; cash $192.7M funds operations into 2025

BioAtla, Inc.

2023-Q1 EPS reported -$0.58

Cash and equivalents $192.7M as of March 31, 2023, down from $215.5M at Dec 31, 2022.
Net loss $27.5M vs $24.3M in Q1 2022; R&D expense rose to $21.7M from $16.9M.
Phase 2 potentially registrational BA3011 UPS study enrolling; LMS cohort readout expected 2H23.
FDA meeting request for BA3011 NSCLC Phase 2 part 2 on track for 1H23; initiation in 2H23.
BA3021 NSCLC interim readout and BA3071 Phase 1 data readout both on track for 2H23.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.